Articles Mentioning Pharmaceuticals Stocks

Results 1 - 10 of 959 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals

Investing | April 13, 2016

AbbVie's Venclexta Notches FDA Win, But Investors Might Want To Temper Enthusiasm

Venclexta's approval in CLL is important, but another drug making its way to market could reduce its use someday.

Investing | April 12, 2016

3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify

Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.

Investing | April 11, 2016

3 Ways Pfizer Can Improve Shareholder Value Without Allergan

With the Allergan merger now dead, Pfizer will probably look to these catalysts to improve its valuation.

Investing | April 10, 2016

3 Big Battles Brewing in Biotech

New drug approvals on the horizon set the stage for a market share brawl.

Investing | April 07, 2016

3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead

With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.

Investing | March 28, 2016

AstraZeneca or AbbVie: Which Is Better for Dividend Growth Investors?

Despite AstraZeneca's strategy to return to growth, income investors may still want to focus their attention on AbbVie.

Investing | March 22, 2016

Which Big Pharma Is the Best Dividend Stock?

Among the largest drugmakers, there are some large dividend yields, but one stands out as most likely to pay off handsomely for investors down the road.

Investing | March 21, 2016

Is This Ironwood Pharmaceuticals' Biggest Threat?

A new competitor to its top-selling drug could be on deck.

Investing | March 08, 2016

Kiss Patent Protection Goodbye for These 3 Blockbuster Drugs in 2016

These three drugs could be losing patent protection in the next 12 months.

Investing | February 20, 2016

Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)

A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.

Results 1 - 10 of 959 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Pharmaceuticals